Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 1,854

The DOI matches its Crossref record; 1,025 of the 1,025 references it cites were found in a registry or an index.

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death

Open access
Al-Khatib, Sana M., Stevenson, William G., Ackerman, Michael J., Bryant, William J., Callans, David J., Curtis, Anne B., Deal, Barbara J., Dickfeld, Timm, Field, Michael E., Fonarow, Gregg C., Gillis, Anne M., Granger, Christopher B., Hammill, Stephen C., Hlatky, Mark A., Joglar, José A., Kay, G. Neal, Matlock, Daniel D., Myerburg, Robert J., Page, Richard L. · 2018 · Journal of the American College of Cardiology

Abstract

Glenn N. Levine, MD, FACC, FAHA, Chair Patrick T. O’Gara, MD, MACC, FAHA, Chair-Elect Jonathan L. Halperin, MD, FACC, FAHA, Immediate Past Chair [¶][1] Sana M. Al-Khatib, MD, MHS, FACC, FAHA Joshua A. Beckman, MD, MS, FAHA Kim K. Birtcher, MS, PharmD, AACC Biykem Bozkurt, MD, PhD, FACC,

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2017.10.054

Cites

1025 of 1025 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Items 401–600 of 1,025

Research works printed but not linked: 286

  1. Priori, 2016, G Ital Cardiol (Rome), 17, 108
  2. Link, 2015, Circulation, 132, e334
  3. Tabereaux, 2009, Mechanisms of VF maintenance: wandering wavelets, mother rotors, or foci, Heart Rhythm, 6, 405, 10.1016/j.hrthm.2008.11.005 · doi:10.1016/j.hrthm.2008.11.005
  4. Zhang, 2016, Electrophysiologic scar substrate in relation to VT: noninvasive high-resolution mapping and risk assessment with ECGI, Pacing Clin Electrophysiol, 39, 781, 10.1111/pace.12882 · doi:10.1111/pace.12882
  5. Myerburg, 2015, Cardiac arrest and sudden cardiac death - Chapter 39, 821
  6. Noda, 2005, Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular outflow tract, J Am Coll Cardiol, 46, 1288, 10.1016/j.jacc.2005.05.077 · DOI · Paper page
  7. Viskin, 2005, The “short-coupled” variant of right ventricular outflow ventricular tachycardia: a not-so-benign form of benign ventricular tachycardia?, J Cardiovasc Electrophysiol, 16, 912, 10.1111/j.1540-8167.2005.50040.x · DOI · Paper page
  8. Nordhues, 2016, Bileaflet mitral valve prolapse and risk of ventricular dysrhythmias and death, J Cardiovasc Electrophysiol, 27, 463, 10.1111/jce.12914 · doi:10.1111/jce.12914
  9. Linzer, 1990, Incremental diagnostic yield of loop electrocardiographic recorders in unexplained syncope, Am J Cardiol, 66, 214, 10.1016/0002-9149(90)90591-N · DOI · Paper page
  10. Turakhia, 2013, Diagnostic utility of a novel leadless arrhythmia monitoring device, Am J Cardiol, 112, 520, 10.1016/j.amjcard.2013.04.017 · DOI · Paper page
  11. Dintzis, 1991, Genetic variation and the meiotic process, Res Publ Assoc Res Nerv Ment Dis, 69, 39
  12. Priori, 2013, HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes, Heart Rhythm, 10, 1932, 10.1016/j.hrthm.2013.05.014 · DOI · Paper page
  13. Laedtke, 2012, Family physicians' awareness and knowledge of the Genetic Information Non-Discrimination Act (GINA), J Genet Couns, 21, 345, 10.1007/s10897-011-9405-6 · DOI
  14. Costantini, 2009, The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention, J Am Coll Cardiol, 53, 471, 10.1016/j.jacc.2008.08.077 · DOI · Paper page
  15. Walker, 2005, Burst bicycle exercise facilitates diagnosis of latent long QT syndrome, Am Heart J, 150, 1059, 10.1016/j.ahj.2005.02.041 · doi:10.1016/j.ahj.2005.02.041
  16. Nannenberg, 2012, Mortality of inherited arrhythmia syndromes: insight into their natural history, Circ Cardiovasc Genet, 5, 183, 10.1161/CIRCGENETICS.111.961102 · DOI
  17. Zareba, 2017, Ranolazine in High-Risk ICD Patients (RAID) Trial, Presented at: Heart Rhythm Society Annual Scientific Sessions
  18. Hirsowitz, 1986, The role of beta blocking agents as adjunct therapy to membrane stabilizing drugs in malignant ventricular arrhythmia, Am Heart J, 111, 852, 10.1016/0002-8703(86)90633-2 · doi:10.1016/0002-8703(86)90633-2
  19. Bardy, 2005, Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure, N Engl J Med, 352, 225, 10.1056/NEJMoa043399 · DOI · Paper page
  20. Rauch, 2010, OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction, Circulation, 122, 2152, 10.1161/CIRCULATIONAHA.110.948562 · DOI · Paper page
  21. Yancy, 2016, J Am Coll Cardiol, 68, 1476, 10.1016/j.jacc.2016.05.011 · DOI · Paper page
  22. 1999, The cardiac insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial, Lancet, 353, 9, 10.1016/S0140-6736(98)11181-9 · DOI · Paper page
  23. Packer, 1996, The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group, N Engl J Med, 334, 1349, 10.1056/NEJM199605233342101 · DOI · Paper page
  24. Dumas, 2016, Emergency PCI in post-cardiac arrest patients without ST-segment elevation pattern: insights from the PROCAT II registry, J Am Coll Cardiol Intv, 9, 1011, 10.1016/j.jcin.2016.02.001 · DOI · Paper page
  25. Ngaage, 2008, Early and late survival after surgical revascularization for ischemic ventricular fibrillation/tachycardia, Ann Thorac Surg, 85, 1278, 10.1016/j.athoracsur.2007.12.035 · doi:10.1016/j.athoracsur.2007.12.035
  26. Layser, 2016, Anomalous coronary arteries: analysis of clinical outcome based upon arterial course and surgical intervention in an adult population, Acad Radiol, 23, 1015, 10.1016/j.acra.2016.03.020 · doi:10.1016/j.acra.2016.03.020
  27. Krittayaphong, 2002, Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study, Am Heart J, 144, e10, 10.1067/mhj.2002.125516 · DOI
  28. Dorian, 2002, Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation, N Engl J Med, 346, 884, 10.1056/NEJMoa013029 · DOI · Paper page
  29. Kudenchuk, 2016, Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest, N Engl J Med, 1711, 10.1056/NEJMoa1514204 · DOI · Paper page
  30. Kudenchuk, 1999, Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation, N Engl J Med, 341, 871, 10.1056/NEJM199909163411203 · DOI · Paper page
  31. Spaulding, 1997, Immediate coronary angiography in survivors of out-of-hospital cardiac arrest, N Engl J Med, 336, 1629, 10.1056/NEJM199706053362302 · DOI · Paper page
  32. Cronier, 2011, Impact of routine percutaneous coronary intervention after out-of-hospital cardiac arrest due to ventricular fibrillation, Crit Care, 15, 10.1186/cc10227 · DOI
  33. Zanuttini, 2012, Impact of emergency coronary angiography on in-hospital outcome of unconscious survivors after out-of-hospital cardiac arrest, Am J Cardiol, 110, 1723, 10.1016/j.amjcard.2012.08.006 · DOI
  34. Dumas, 2016, Emergency PCI in post-cardiac arrest patients without ST-segment elevation pattern: insights from the PROCAT II registry, J Am Coll Cardiol Intv, 9, 1011, 10.1016/j.jcin.2016.02.001 · DOI · Paper page
  35. Nademanee, 2000, Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy, Circulation, 102, 742, 10.1161/01.CIR.102.7.742 · DOI · Paper page
  36. Belhassen, 1984, Use of intravenous verapamil for ventricular tachycardia, Am J Cardiol, 54, 1131, 10.1016/S0002-9149(84)80158-7 · DOI
  37. Buxton, 1987, Hazards of intravenous verapamil for sustained ventricular tachycardia, Am J Cardiol, 59, 1107, 10.1016/0002-9149(87)90857-5 · DOI
  38. Zipes, 2006, J Am Coll Cardiol, 48, e247, 10.1016/j.jacc.2006.07.010 · DOI · Paper page
  39. Perkins, 2015, Circulation, 132, 1286, 10.1161/CIR.0000000000000144 · DOI · Paper page
  40. Link, 2015, Circulation, 132, e334
  41. Joglar, 2016, Out-of-hospital cardiac arrest–are drugs ever the answer?, N Engl J Med, 374, 1781, 10.1056/NEJMe1602790 · doi:10.1056/nejme1602790
  42. 1997, A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias, N Engl J Med, 337, 1576, 10.1056/NEJM199711273372202 · DOI · Paper page
  43. Connolly, 2000, Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study, Eur Heart J, 21, 2071, 10.1053/euhj.2000.2476 · DOI · Paper page
  44. Anderson, 2014, ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2304, 10.1016/j.jacc.2014.03.016 · DOI · Paper page
  45. Morikawa, 2010, Letter by Morikawa et al regarding article, “coronary artery spasm: a 2009 update”, Circulation, 121, e16, 10.1161/CIR.0b013e3181ce1bcc · doi:10.1161/cir.0b013e3181ce1bcc
  46. Ascione, 2004, Predictors of new malignant ventricular arrhythmias after coronary surgery: a case-control study, J Am Coll Cardiol, 43, 1630, 10.1016/j.jacc.2003.11.056 · DOI
  47. Saxon, 1995, Monomorphic versus polymorphic ventricular tachycardia after coronary artery bypass grafting, Am J Cardiol, 75, 403, 10.1016/S0002-9149(99)80566-9 · doi:10.1016/s0002-9149(99)80566-9
  48. Bardy, 2005, Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure, N Engl J Med, 352, 225, 10.1056/NEJMoa043399 · DOI · Paper page
  49. Moss, 2002, Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction, N Engl J Med, 346, 877, 10.1056/NEJMoa013474 · DOI · Paper page
  50. Moss, 1996, Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators, N Engl J Med, 335, 1933, 10.1056/NEJM199612263352601 · DOI · Paper page
  51. Owens, 2002, Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator, Am Heart J, 144, 440, 10.1067/mhj.2002.125501 · DOI
  52. Buxton, 1999, A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators, N Engl J Med, 341, 1882, 10.1056/NEJM199912163412503 · DOI · Paper page
  53. Buxton, 2006, ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards, J Am Coll Cardiol, 48, 2360, 10.1016/j.jacc.2006.09.020 · DOI · Paper page
  54. Anderson, 2014, ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2304, 10.1016/j.jacc.2014.03.016 · DOI · Paper page
  55. Buxton, 2000, Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators, N Engl J Med, 342, 1937, 10.1056/NEJM200006293422602 · DOI · Paper page
  56. Kusumoto, 2014, HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials, J Am Coll Cardiol, 64, 1143, 10.1016/j.jacc.2014.04.008 · DOI · Paper page
  57. Sapp, 2016, Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs, N Engl J Med, 375, 111, 10.1056/NEJMoa1513614 · DOI · Paper page
  58. Echt, 1991, Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial, N Engl J Med, 324, 781, 10.1056/NEJM199103213241201 · DOI · Paper page
  59. Steinberg, 1999, New-onset sustained ventricular tachycardia after cardiac surgery, Circulation, 99, 903, 10.1161/01.CIR.99.7.903 · DOI
  60. Claro, 2015, Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death, Cochrane Database Syst Rev, 12
  61. Bunch, 2011, Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks, Pacing Clin Electrophysiol, 34, 1600, 10.1111/j.1540-8159.2011.03208.x · DOI · Paper page
  62. 1992, Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators, N Engl J Med, 327, 227, 10.1056/NEJM199207233270403 · DOI · Paper page
  63. Kuck, 2000, Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH), Circulation, 102, 748, 10.1161/01.CIR.102.7.748 · DOI · Paper page
  64. Berntsen, 1993, Surgical revascularization in the treatment of ventricular tachycardia and fibrillation exposed by exercise-induced ischaemia, Eur Heart J, 14, 1297, 10.1093/eurheartj/14.10.1297 · doi:10.1093/eurheartj/14.10.1297
  65. Greulich, 2013, CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis, J Am Coll Cardiol Img, 6, 501, 10.1016/j.jcmg.2012.10.021 · DOI · Paper page
  66. Piers, 2013, Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy: implications for the ablation strategy, Circ Arrhythm Electrophysiol, 6, 875, 10.1161/CIRCEP.113.000537 · DOI · Paper page
  67. Ackerman, 2011, HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA), Europace, 13, 1077, 10.1093/europace/eur245 · DOI · Paper page
  68. Coleman, 2016, Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis: a systematic review and meta-analysis, J Am Coll Cardiol Img
  69. 1997, A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias, N Engl J Med, 337, 1576, 10.1056/NEJM199711273372202 · DOI · Paper page
  70. Kuck, 2000, Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH), Circulation, 102, 748, 10.1161/01.CIR.102.7.748 · DOI · Paper page
  71. Raitt, 2001, “Stable” ventricular tachycardia is not a benign rhythm: insights from the Antiarrhythmics versus Implantable Defibrillators (AVID) registry, Circulation, 103, 244, 10.1161/01.CIR.103.2.244 · DOI
  72. Middlekauff, 1993, Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope, J Am Coll Cardiol, 21, 110, 10.1016/0735-1097(93)90724-F · DOI · Paper page
  73. Claro, 2015, Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death, Cochrane Database Syst Rev, 12
  74. Gatzoulis, 2013, Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation, Circ Arrhythm Electrophysiol, 6, 504, 10.1161/CIRCEP.113.000216 · DOI
  75. Hilfiker, 2015, Utility of electrophysiological studies to predict arrhythmic events, World J Cardiol, 7, 344, 10.4330/wjc.v7.i6.344 · DOI
  76. Thomas, 2008, Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality, Am Heart J, 155, 87, 10.1016/j.ahj.2007.09.010 · DOI
  77. Bardy, 2005, Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure, N Engl J Med, 352, 225, 10.1056/NEJMoa043399 · DOI · Paper page
  78. Bristow, 2004, Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure, N Engl J Med, 350, 2140, 10.1056/NEJMoa032423 · DOI · Paper page
  79. Desai, 2004, Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials, JAMA, 292, 2874, 10.1001/jama.292.23.2874 · DOI · Paper page
  80. Kadish, 2004, Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy, N Engl J Med, 350, 2151, 10.1056/NEJMoa033088 · DOI · Paper page
  81. Anselme, 2013, Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders, Heart Rhythm, 10, 1492, 10.1016/j.hrthm.2013.06.020 · DOI
  82. Pasotti, 2008, Long-term outcome and risk stratification in dilated cardiolaminopathies, J Am Coll Cardiol, 52, 1250, 10.1016/j.jacc.2008.06.044 · DOI · Paper page
  83. Van Berlo, 2005, Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death?, J Mol Med, 83, 79, 10.1007/s00109-004-0589-1 · DOI · Paper page
  84. van Rijsingen, 2012, Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study, J Am Coll Cardiol, 59, 493, 10.1016/j.jacc.2011.08.078 · DOI · Paper page
  85. Connolly, 2006, Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial, JAMA, 295, 165, 10.1001/jama.295.2.165 · DOI · Paper page
  86. Tung, 2015, Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: an International VT Ablation Center Collaborative Group study, Heart Rhythm, 12, 1997, 10.1016/j.hrthm.2015.05.036 · DOI · Paper page
  87. Piers, 2013, Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy: implications for the ablation strategy, Circ Arrhythm Electrophysiol, 6, 875, 10.1161/CIRCEP.113.000537 · DOI · Paper page
  88. Groeneweg, 2015, Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients and family members, Circ Cardiovasc Genet, 8, 437, 10.1161/CIRCGENETICS.114.001003 · DOI · Paper page
  89. Marcus, 2013, Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians, J Am Coll Cardiol, 61, 1945, 10.1016/j.jacc.2013.01.073 · DOI · Paper page
  90. Quarta, 2011, Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria, Circulation, 123, 2701, 10.1161/CIRCULATIONAHA.110.976936 · DOI · Paper page
  91. Hershberger, 2009, Genetic evaluation of cardiomyopathy–a Heart Failure Society of America practice guideline, J Card Fail, 15, 83, 10.1016/j.cardfail.2009.01.006 · DOI · Paper page
  92. Rigato, 2013, Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy, Circ Cardiovasc Genet, 6, 533, 10.1161/CIRCGENETICS.113.000288 · DOI · Paper page
  93. van Rijsingen, 2012, Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study, J Am Coll Cardiol, 59, 493, 10.1016/j.jacc.2011.08.078 · DOI · Paper page
  94. Christiaans, 2009, Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: the patients' perspective, Am J Med Genet, 149a, 1444, 10.1002/ajmg.a.32915 · DOI
  95. Hamang, 2012, Predictors of heart-focused anxiety in patients undergoing genetic investigation and counseling of long QT syndrome or hypertrophic cardiomyopathy: a one year follow-up, J Genet Counsel, 21, 72, 10.1007/s10897-011-9393-6 · DOI
  96. Zhu, 1998, The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy, Pacing Clin Electrophysiol, 21, 299, 10.1111/j.1540-8159.1998.tb01109.x · DOI
  97. Gersh, 2011, J Am Coll Cardiol, 58, e212, 10.1016/j.jacc.2011.06.011 · DOI · Paper page
  98. Saeed, 2001, Role of invasive electrophysiologic testing in risk stratification for sudden cardiac death, J Invasive Cardiol, 13, 758
  99. Winkel, 2002, Myocarditis. Curr Treat Options, Cardiovasc Med, 4, 455
  100. Huang, 2013, Acute myocarditis and ventricular fibrillation as initial presentation of pediatric systemic lupus erythematosus, Rheumatol Int, 33, 1093, 10.1007/s00296-011-2240-0 · doi:10.1007/s00296-011-2240-0
  101. Muratore, 1997, Implantable cardioverter defibrillators in patients with Chagas' disease: are they different from patients with coronary disease?, Pacing Clin Electrophysiol, 20, 194, 10.1111/j.1540-8159.1997.tb04841.x · doi:10.1111/j.1540-8159.1997.tb04841.x
  102. d'Avila, 2002, New perspectives on catheter-based ablation of ventricular tachycardia complicating Chagas' disease: experimental evidence of the efficacy of near infrared lasers for catheter ablation of Chagas' VT, J Interv Card Electrophysiol, 7, 23, 10.1023/A:1020811915133 · doi:10.1023/a:1020811915133
  103. Coleman, 2016, Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis: a systematic review and meta-analysis, J Am Coll Cardiol Img, 10, 411, 10.1016/j.jcmg.2016.05.009 · DOI · Paper page
  104. Greulich, 2013, CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis, J Am Coll Cardiol Img, 6, 501, 10.1016/j.jcmg.2012.10.021 · DOI · Paper page
  105. Naruse, 2014, Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis, Circ Arrhythm Electrophysiol, 7, 407, 10.1161/CIRCEP.113.000734 · DOI
  106. Birnie, 2014, HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis, Heart Rhythm, 11, 1305, 10.1016/j.hrthm.2014.03.043 · DOI · Paper page
  107. Frohlich, 2013, Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation, Heart, 99, 1158, 10.1136/heartjnl-2013-304185 · DOI
  108. Kao, 2012, Wearable defibrillator use in heart failure (WIF): results of a prospective registry, BMC Cardiovasc Disord, 12, 123, 10.1186/1471-2261-12-123 · DOI
  109. Vakil, 2017, Impact of implantable cardioverter-defibrillators on waitlist mortality among patients awaiting heart transplantation. An UNOS/OPTN Analysis, JACC Clin Electrophysiol, 3, 33, 10.1016/j.jacep.2016.07.010 · DOI
  110. 1999, Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF), Lancet, 353, 2001, 10.1016/S0140-6736(99)04440-2 · DOI · Paper page
  111. Pitt, 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 348, 1309, 10.1056/NEJMoa030207 · DOI · Paper page
  112. Desai, 2015, Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients, Eur Heart J, 36, 1990, 10.1093/eurheartj/ehv186 · DOI · Paper page
  113. Vakil, 2016, Implantable cardioverter-defibrillator use in patients with left ventricular assist devices: a systematic review and meta-analysis, JACC Heart Fail, 4, 772, 10.1016/j.jchf.2016.05.003 · DOI
  114. Cantillon, 2010, Improved survival among ventricular assist device recipients with a concomitant implantable cardioverter-defibrillator, Heart Rhythm, 7, 466, 10.1016/j.hrthm.2009.12.022 · doi:10.1016/j.hrthm.2009.12.022
  115. Slaughter, 2011, Destination therapy with left ventricular assist devices: patient selection and outcomes, Curr Opin Cardiol, 26, 232, 10.1097/HCO.0b013e328345aff4 · doi:10.1097/hco.0b013e328345aff4
  116. Anselme, 2013, Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders, Heart Rhythm, 10, 1492, 10.1016/j.hrthm.2013.06.020 · DOI
  117. van Rijsingen, 2012, Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study, J Am Coll Cardiol, 59, 493, 10.1016/j.jacc.2011.08.078 · DOI · Paper page
  118. Meune, 2006, Primary prevention of sudden death in patients with lamin A/C gene mutations, N Engl J Med, 354, 209, 10.1056/NEJMc052632 · DOI · Paper page
  119. Pasotti, 2008, Long-term outcome and risk stratification in dilated cardiolaminopathies, J Am Coll Cardiol, 52, 1250, 10.1016/j.jacc.2008.06.044 · DOI · Paper page
  120. Van Berlo, 2005, Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death?, J Mol Med, 83, 79, 10.1007/s00109-004-0589-1 · DOI · Paper page
  121. Epstein, 2008, J Am Coll Cardiol, 51, e1, 10.1016/j.jacc.2008.02.032 · DOI · Paper page
  122. Kumar, 2016, Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers, J Am Coll Cardiol, 68, 2299, 10.1016/j.jacc.2016.08.058 · DOI · Paper page
  123. Goldenberg, 2011, Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals, J Am Coll Cardiol, 57, 51, 10.1016/j.jacc.2010.07.038 · DOI · Paper page
  124. Nannenberg, 2012, Mortality of inherited arrhythmia syndromes: insight into their natural history, Circ Cardiovasc Genet, 5, 183, 10.1161/CIRCGENETICS.111.961102 · DOI
  125. Priori, 2002, Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia, Circulation, 106, 69, 10.1161/01.CIR.0000020013.73106.D8 · DOI · Paper page
  126. Wedekind, 2009, QT interval prolongation and risk for cardiac events in genotyped LQTS-index children, Eur J Pediatr, 168, 1107, 10.1007/s00431-008-0896-6 · DOI
  127. Kaufman, 2008, Risk of death in the long QT syndrome when a sibling has died, Heart Rhythm, 5, 831, 10.1016/j.hrthm.2008.02.029 · DOI
  128. Kimbrough, 2001, Clinical implications for affected parents and siblings of probands with long-QT syndrome, Circulation, 104, 557, 10.1161/hc3001.093501 · DOI
  129. Hobbs, 2006, Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome, JAMA, 296, 1249, 10.1001/jama.296.10.1249 · DOI · Paper page
  130. Priori, 2004, Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers, JAMA, 292, 1341, 10.1001/jama.292.11.1341 · DOI · Paper page
  131. Priori, 2003, Risk stratification in the long-QT syndrome, N Engl J Med, 348, 1866, 10.1056/NEJMoa022147 · DOI · Paper page
  132. Paludan-Muller, 2017, Integration of 60,000 exomes and ACMG guidelines question the role of catecholaminergic polymorphic ventricular tachycardia-associated variants, Clin Genet, 91, 63, 10.1111/cge.12847 · DOI
  133. Giustetto, 2011, Long-term follow-up of patients with short QT syndrome, J Am Coll Cardiol, 58, 587, 10.1016/j.jacc.2011.03.038 · DOI · Paper page
  134. Mahida, 2015, Role of electrophysiological studies in predicting risk of ventricular arrhythmia in early repolarization syndrome, J Am Coll Cardiol, 65, 151, 10.1016/j.jacc.2014.10.043 · DOI
  135. Mazzanti, 2014, Novel insight into the natural history of short QT syndrome, J Am Coll Cardiol, 63, 1300, 10.1016/j.jacc.2013.09.078 · DOI · Paper page
  136. Rodriguez-Manero, 2016, Monomorphic ventricular tachycardia in patients with Brugada syndrome: a multicenter retrospective study, Heart Rhythm, 13, 669, 10.1016/j.hrthm.2015.10.038 · DOI
  137. Moss, 2000, Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome, Circulation, 101, 616, 10.1161/01.CIR.101.6.616 · DOI · Paper page
  138. Vincent, 2009, High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment “failures”, Circulation, 119, 215, 10.1161/CIRCULATIONAHA.108.772533 · DOI · Paper page
  139. Hobbs, 2006, Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome, JAMA, 296, 1249, 10.1001/jama.296.10.1249 · DOI · Paper page
  140. Mazzanti, 2016, Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3, J Am Coll Cardiol, 67, 1053, 10.1016/j.jacc.2015.12.033 · DOI · Paper page
  141. Nannenberg, 2012, Mortality of inherited arrhythmia syndromes: insight into their natural history, Circ Cardiovasc Genet, 5, 183, 10.1161/CIRCGENETICS.111.961102 · DOI
  142. Wedekind, 2009, QT interval prolongation and risk for cardiac events in genotyped LQTS-index children, Eur J Pediatr, 168, 1107, 10.1007/s00431-008-0896-6 · DOI
  143. Hofferberth, 2014, Left thoracoscopic sympathectomy for cardiac denervation in patients with life-threatening ventricular arrhythmias. J Thorac Cardiovasc, Surg, 147, 404
  144. Bai, 2009, Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing, Circ Arrhythm Electrophysiol, 2, 6, 10.1161/CIRCEP.108.782888 · DOI
  145. Costa, 2012, Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long QT syndrome, Heart Rhythm, 9, 892, 10.1016/j.hrthm.2012.01.020 · DOI
  146. Kim, 2010, Trigger-specific risk factors and response to therapy in long QT syndrome type 2, Heart Rhythm, 7, 1797, 10.1016/j.hrthm.2010.09.011 · DOI
  147. Migdalovich, 2011, Mutation and gender-specific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome, Heart Rhythm, 8, 1537, 10.1016/j.hrthm.2011.03.049 · DOI
  148. Priori, 2004, Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers, JAMA, 292, 1341, 10.1001/jama.292.11.1341 · DOI · Paper page
  149. Goldenberg, 2011, Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals, J Am Coll Cardiol, 57, 51, 10.1016/j.jacc.2010.07.038 · DOI · Paper page
  150. Priori, 2003, Risk stratification in the long-QT syndrome, N Engl J Med, 348, 1866, 10.1056/NEJMoa022147 · DOI · Paper page
  151. Wilde, 2016, Clinical aspects of type 3 long-QT syndrome: an international multicenter study, Circulation, 134, 872, 10.1161/CIRCULATIONAHA.116.021823 · DOI · Paper page
  152. Garson, 1993, The long QT syndrome in children. An international study of 287 patients, Circulation, 87, 1866, 10.1161/01.CIR.87.6.1866 · DOI · Paper page
  153. Dorostkar, 1999, Long-term follow-up of patients with long-QT syndrome treated with beta-blockers and continuous pacing, Circulation, 100, 2431, 10.1161/01.CIR.100.24.2431 · DOI
  154. Eldar, 1992, Combined use of beta-adrenergic blocking agents and long-term cardiac pacing for patients with the long QT syndrome, J Am Coll Cardiol, 20, 830, 10.1016/0735-1097(92)90180-U · DOI
  155. Moss, 1991, Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome, Circulation, 84, 1524, 10.1161/01.CIR.84.4.1524 · DOI · Paper page
  156. Bos, 2013, Left cardiac sympathetic denervation in long QT syndrome: analysis of therapeutic nonresponders, Circ Arrhythm Electrophysiol, 6, 705, 10.1161/CIRCEP.113.000102 · doi:10.1161/circep.113.000102
  157. Li, 2008, Video-assisted thoracoscopic left cardiac sympathetic denervation: a reliable minimally invasive approach for congenital long-QT syndrome, Ann Thorac Surg, 86, 1955, 10.1016/j.athoracsur.2008.07.100 · doi:10.1016/j.athoracsur.2008.07.100
  158. Zhang, 2015, Identification of low-risk adult congenital LQTS patients, J Cardiovasc Electrophysiol, 26, 853, 10.1111/jce.12686 · doi:10.1111/jce.12686
  159. Spazzolini, 2009, Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy, J Am Coll Cardiol, 54, 832, 10.1016/j.jacc.2009.05.029 · DOI
  160. Hayashi, 2009, Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia, Circulation, 119, 2426, 10.1161/CIRCULATIONAHA.108.829267 · DOI · Paper page
  161. Collura, 2009, Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery, Heart Rhythm, 6, 752, 10.1016/j.hrthm.2009.03.024 · DOI · Paper page
  162. Schneider, 2013, Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome, Clin Res Cardiol, 102, 33, 10.1007/s00392-012-0492-7 · DOI
  163. Priori, 2002, Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia, Circulation, 106, 69, 10.1161/01.CIR.0000020013.73106.D8 · DOI · Paper page
  164. Adler, 2016, Patient outcomes from a specialized inherited arrhythmia clinic, Circ Arrhythm Electrophysiol, 9, e003440, 10.1161/CIRCEP.115.003440 · DOI
  165. Olde Nordkamp, 2016, Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: a systematic review and meta-analysis of inappropriate shocks and complications, Heart Rhythm, 13, 443, 10.1016/j.hrthm.2015.09.010 · DOI · Paper page
  166. De Ferrari, 2015, Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation, Circulation, 131, 2185, 10.1161/CIRCULATIONAHA.115.015731 · DOI · Paper page
  167. Wilde, 2008, Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia, N Engl J Med, 358, 2024, 10.1056/NEJMoa0708006 · DOI · Paper page
  168. Zhang, 2015, Long-QT syndrome and therapy for attention deficit/hyperactivity disorder, J Cardiovasc Electrophysiol, 26, 1039, 10.1111/jce.12739 · DOI
  169. Jabbari, 2013, New exome data question the pathogenicity of genetic variants previously associated with catecholaminergic polymorphic ventricular tachycardia, Circ Cardiovasc Genetics, 6, 481, 10.1161/CIRCGENETICS.113.000118 · DOI
  170. Paludan-Muller, 2017, Integration of 60,000 exomes and acmg guidelines question the role of catecholaminergic polymorphic ventricular tachycardia-associated variants, Clin Genet, 91, 63, 10.1111/cge.12847 · DOI
  171. Gehi, 2006, Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis, J Cardiovasc Electrophysiol, 17, 577, 10.1111/j.1540-8167.2006.00455.x · DOI · Paper page
  172. Hiraoka, 2013, Prognosis and risk stratification of young adults with Brugada syndrome, J Electrocardiol, 46, 279, 10.1016/j.jelectrocard.2013.04.003 · DOI
  173. Priori, 2012, Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry, J Am Coll Cardiol, 59, 37, 10.1016/j.jacc.2011.08.064 · DOI · Paper page
  174. Probst, 2010, Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada syndrome registry, Circulation, 121, 635, 10.1161/CIRCULATIONAHA.109.887026 · DOI · Paper page
  175. Delise, 2011, Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach, Eur Heart J, 32, 169, 10.1093/eurheartj/ehq381 · DOI · Paper page
  176. Kusumoto, 2018, J Am Coll Cardiol, 72, 1653, 10.1016/j.jacc.2017.10.052 · DOI
  177. Crotti, 2012, Spectrum and prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing, J Am Coll Cardiol, 60, 1410, 10.1016/j.jacc.2012.04.037 · DOI · Paper page
  178. Probst, 2009, SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome, Circ Cardiovasc Genet, 2, 552, 10.1161/CIRCGENETICS.109.853374 · DOI · Paper page
  179. Risgaard, 2013, High prevalence of genetic variants previously associated with Brugada syndrome in new exome data, Clinical Genetics, 84, 489, 10.1111/cge.12126 · DOI
  180. Priori, 2013, HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes, Heart Rhythm, 10, 1932, 10.1016/j.hrthm.2013.05.014 · DOI · Paper page
  181. Rodriguez-Manero, 2016, Monomorphic ventricular tachycardia in patients with Brugada syndrome: a multicenter retrospective study, Heart Rhythm, 13, 669, 10.1016/j.hrthm.2015.10.038 · DOI
  182. Conte, 2015, Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience, J Am Coll Cardiol, 65, 879, 10.1016/j.jacc.2014.12.031 · DOI · Paper page
  183. Priori, 2002, Natural history of Brugada syndrome: insights for risk stratification and management, Circulation, 105, 1342, 10.1161/hc1102.105288 · DOI · Paper page
  184. Siebermair, 2016, Early repolarization pattern is the strongest predictor of arrhythmia recurrence in patients with idiopathic ventricular fibrillation: results from a single centre long-term follow-up over 20 years, Europace, 18, 718, 10.1093/europace/euv301 · DOI
  185. Giustetto, 2011, Long-term follow-up of patients with short QT syndrome, J Am Coll Cardiol, 58, 587, 10.1016/j.jacc.2011.03.038 · DOI · Paper page
  186. Mazzanti, 2014, Novel insight into the natural history of short QT syndrome, J Am Coll Cardiol, 63, 1300, 10.1016/j.jacc.2013.09.078 · DOI · Paper page
  187. Giustetto, 2006, Short QT syndrome: clinical findings and diagnostic-therapeutic implications, Eur Heart J, 27, 2440, 10.1093/eurheartj/ehl185 · DOI · Paper page
  188. Iribarren, 2014, Short QT in a cohort of 1.7 million persons: prevalence, correlates, and prognosis, Ann Noninvasive Electrocardiol, 19, 490, 10.1111/anec.12157 · DOI
  189. Gollob, 2011, Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper, Can J Cardiol, 27, 232, 10.1016/j.cjca.2010.12.078 · DOI
  190. Gill, 1993, Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology, Am Heart J, 126, 1126, 10.1016/0002-8703(93)90664-U · DOI
  191. Gill, 1992, Comparison of verapamil and diltiazem in the suppression of idiopathic ventricular tachycardia, Pacing Clin Electrophysiol, 15, 2122, 10.1111/j.1540-8159.1992.tb03033.x · DOI
  192. Kontos, 2011, Treatment and outcomes in patients with myocardial infarction treated with acute beta–blocker therapy: results from the American College of Cardiology's NCDR(R), Am Heart J, 161, 864, 10.1016/j.ahj.2011.01.006 · DOI
  193. Levine, 1996, Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group, J Am Coll Cardiol, 27, 67, 10.1016/0735-1097(95)00427-0 · DOI · Paper page
  194. Noda, 2005, Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular outflow tract, J Am Coll Cardiol, 46, 1288, 10.1016/j.jacc.2005.05.077 · DOI · Paper page
  195. Viskin, 2005, The “short-coupled” variant of right ventricular outflow ventricular tachycardia: a not-so-benign form of benign ventricular tachycardia?, J Cardiovasc Electrophysiol, 16, 912, 10.1111/j.1540-8167.2005.50040.x · DOI · Paper page
  196. Krittayaphong, 2002, Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study, Am Heart J, 144, e10, 10.1067/mhj.2002.125516 · DOI
  197. Ling, 2014, Radiofrequency ablation versus antiarrhythmic medication for treatment of ventricular premature beats from the right ventricular outflow tract: prospective randomized study, Circ Arrhythm Electrophysiol, 7, 237, 10.1161/CIRCEP.113.000805 · DOI · Paper page
  198. Badhwar, 2007, Idiopathic ventricular tachycardia: diagnosis and management, Curr Probl Cardiol, 32, 7, 10.1016/j.cpcardiol.2006.10.002 · DOI
  199. Connolly, 1999, Meta-analysis of antiarrhythmic drug trials, Am J Cardiol, 84, 90R, 10.1016/S0002-9149(99)00708-0 · DOI
  200. Ling, 2014, Radiofrequency ablation versus antiarrhythmic medication for treatment of ventricular premature beats from the right ventricular outflow tract: prospective randomized study, Circ Arrhythm Electrophysiol, 7, 237, 10.1161/CIRCEP.113.000805 · DOI · Paper page

200 of 286 shown

Cited by

See all 1,854

Metadata

Authors
Al-Khatib, S. M., Stevenson, W. G., Ackerman, M. J., Bryant, W. J., Callans, D. J., Curtis, A. B., Deal, B. J., Dickfeld, T., Field, M. E., Fonarow, G. C., Gillis, A. M., Granger, C. B., Hammill, S. C., Hlatky, M. A., Joglar, J. A., Kay, G. N., Matlock, D. D., Myerburg, R. J., & Page, R. L.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2018-10
Volume
72
Issue
14
Pages
e91-e220
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2940793653
Cited by
1,854
References
1,025
FWCI
144.51
Type
journal article
Language
en
Update notices
erratum (2018-10-02)
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.